Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Yutaka Niihara, MD, MPH
Researcher Professor of Medicine
David Geffen School of Medicine at UCLA
1124 West Carson Street C-1, Room 12
Torrance, California, United States
Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease in which he co-founded the bio-pharmaceutical company, Emmaus Life Sciences, Inc. It is now in phase III clinical trial involving 32 sites throughout US with FDA Drug Designation and Fast Track Designation. Additionally, his laboratory focuses on regenerative medicine using cell sheet technology. This treatment uses autologous progenitor cell sheets to repair damaged organs such as cornea epithelium and myocardium. Currently, he is the Professor of Medicine at the David Geffen School of Medicine at UCLA. His areas of research are sickle cell disease, cancer & carcinogenesis, blood & blood products & transfusions, biological markers and oncology specialized techniques in research such as red cell enzyme studies and red cell nucleotide analysis.
+myBinderRelated Content
-
Sancilio Pharmaceuticals Company, Inc. (SPCI) Receives Rare Pediatric Disease Designation From the US Food and Drug ...Sancilio Pharmaceuticals Company, Inc. (...
-
The University of North Carolina Comprehensive Sickle Cell ProgramTo carry out basic, translational and cl...
-
DDCF Awards $6 Million for Sickle Cell Disease ResearchThe Doris Duke Charitable Foundation has...
-
Data Brief: Healthcare Utilization for Vaso-Occlusive Episodes by People with Sickle Cell Disease in California and ...Many people with sickle cell disease (SC...
-
Swee Lay Thein, MB, BS, FRCP, FRCPath, DSSwee Lay Thein is the Chief of the Sickl...
-
Julie Makani, FRCP, PhDDr. Julie Makani is an Associate Profess...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
